Technology | October 03, 2014

Gore Receives FDA Approval for Endovascular Treatment of In-stent Restenosis with the Gore Viabahn Endoprosthesis

Innovative treatment offers long-term solution for ISR

W.L. Gore FDA Approval Gore Viabahn Endoprosthesis

October 3, 2014 — W. L. Gore & Associates Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Gore Viabahn Endoprosthesis for interventional treatment of in-stent restenosis in the superficial femoral artery (SFA). Now indicated for the treatment of failed bare metal stents (BMS) in the SFA, the Gore Viabahn device has more vascular indications supported by more level 1 clinical trials than any other self-expanding peripheral stent or stent-graft.

In-stent restenosis or reocclusion occurs in a significant number of patients over the course of one year after bare metal stenting, and these rates are highly dependent on the severity of disease. Treatment options for in-stent restenosis include angioplasty, repeat stenting with another BMS, and surgical bypass. The Gore Viabahn device changes the current treatment paradigm for in-stent restenosis by re-lining the failed BMS and adjacent diseased vessel, providing a long-term physical barrier that extends the life of the intervention.

The safety and efficacy of the Gore Viabahn device in this indication was supported by the randomized RELINE Clinical Study, in which the lesions in both arms of the study averaged more than 17 cm in length. The study found that the device is statistically superior in target lesion primary patency than percutaneous transluminal angioplasty, or PTA, which is the most common frontline interventional treatment of in-stent restenosis.

The RELINE Clinical Study found that:

  • Subjects in the Gore Viabahn device arm of the RELINE trial were approximately three times less likely than those in the PTA arm to require a target lesion revascularization (TLR) after one year.
  • After 12 months, the Gore Viabahn Endoprosthesis showed a primary patency of 74.8 percent, more than 45 percent higher than PTA.
  • With the longest available 25 cm stent-graft, heparin surface, and ePTFE liner, the Gore Viabahn Device is a long-lasting solution for treatment of failed bare stents.

“The treatment of failed bare metal stents has long been a perplexing problem for vascular specialists, in which only a few treatments are FDA-approved and limited compelling clinical data exist. This new indication for the Gore device and the accompanying data from the RELINE trial provide physicians with the means to intervene confidently on a failed bare metal stent, extending the life of the intervention and improving patient outcomes,” said Peter A. Soukas, M.D., assistant professor of medicine, Brown Medical School.

The Gore Viabahn Endoprosthesis is the lowest profile, most flexible, self-expanding stent-graft available. It is the only stent-graft to receive approval for the SFA (de novo, restenotic, and in-stent restenotic disease), iliac artery, and arteriovenous access revision. The device is constructed with a durable, reinforced, biocompatible, expanded ePTFE liner and attached to an external nitinol stent structure. The ePTFE luminal surface of the Gore Viabahn device features the CBAS Heparin Surface intended to provide sustained thromboresistance.

For more information: www.goremedical.com


Related Content

News | Endovascular Aortic Repair

March 22, 2022 – A retrospective evaluation of 600 fenestrated-branched endovascular aortic repairs for the treatment of ...

Home March 22, 2022
Home
News | Endovascular Aortic Repair

February 18, 2022 – Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of ...

Home February 18, 2022
Home
News | Endovascular Aortic Repair

May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a ...

Home May 12, 2021
Home
News | Endovascular Aortic Repair

February 23, 2021 — Medtronic has voluntarily issued a global recall of unused Medtronic Valiant Navion thoracic stent ...

Home February 23, 2021
Home
News | Endovascular Aortic Repair

January 31, 2020 – The Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) released new reporting ...

Home January 31, 2020
Home
News | Endovascular Aortic Repair

January 29, 2020 – The presence of a blood clot on the wall of the aorta in people with abdominal aortic aneurysms (AAA) ...

Home January 29, 2020
Home
News | Endovascular Aortic Repair

November 7, 2019 — The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for ...

Home November 11, 2019
Home
News | Endovascular Aortic Repair

November 21, 2018 — New research in the December edition of the Journal of Vascular Surgery suggests significant ...

Home November 21, 2018
Home
News | Endovascular Aortic Repair

October 8, 2018 — Endologix Inc. received notice that the U.S. Food and Drug Administration (FDA) has classified a ...

Home October 08, 2018
Home
Feature | Endovascular Aortic Repair | Andrei Churyla, M.D., S. Chris Malaisrie, M.D.

Here are several considerations for physicians when choosing endovascular stent grafts used to treat aortic aneurysms ...

Home February 05, 2018
Home
Subscribe Now